-+ 0.00%
-+ 0.00%
-+ 0.00%

Leerink Partners Maintains Outperform on Veradermics, Raises Price Target to $150

Benzinga·11/09/2026 21:53:53
Listen to the news
Leerink Partners analyst Marc Goodman maintains Veradermics (NYSE:MANE) with a Outperform and raises the price target from $135 to $150.